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Abstract
Objective: Lung cancer patients often experience profound physical and psychosocial changes as a result of 
disease progression or treatment side effects. Fatigue, pain, dyspnea, depression, and sleep disturbances appear 
to be the most common symptoms in such patients. The objective of the present study was to examine the 
prevalence of symptoms in lung cancer patients in order to identify subgroups (clusters) of patients, grouped 
according to the magnitude of the symptoms, as well as to compare the quality of life among the identified 
subgroups. Methods: A cross-sectional study involving agglomerative hierarchical clustering. A total of 50 lung 
cancer patients were evaluated in terms of their demographic characteristics and their scores on three quality 
of life questionnaires, namely the 30-item European Organization for Research and Treatment of Cancer Core 
Quality of Life Questionnaire (EORTC QLQ-C30), the Functional Assessment of Cancer Therapy-Lung, and the 
Medical Outcomes Study 36-item Short-form Survey. The cluster analysis took into account the magnitude of 
the most prevalent symptoms as assessed by the EORTC QLQ-C30 symptom scale scores; those symptoms were 
fatigue, pain, dyspnea, and insomnia. Results: Three clusters (subgroups)_of patients were identified on the 
basis of the magnitude of the four most prevalent symptoms. The three subgroups of patients were as follows: 
patients with mild symptoms (n = 30; 60%); patients with moderate symptoms (n = 14; 28%); and patients 
with severe symptoms (n = 6; 12%). The subgroup of patients with severe symptoms had the worst quality of 
life, as assessed by the total scores and by the integrated domains of all three instruments. Conclusions: This 
study highlights the importance of symptom cluster assessment as an important tool to assess the quality of 
life of patients with chronic diseases, such as lung cancer.
Keywords: Signs and symptoms; Cluster analysis; Lung neoplasms; Quality of life; Questionnaires; Palliative 
care.
Resumo
Objetivo: Muitas vezes pacientes com câncer de pulmão vivenciam mudanças físicas e psicossociais profundas 
que resultam da progressão da doença ou dos efeitos colaterais do tratamento. Fadiga, dor, dispneia, depressão e 
distúrbios do sono parecem ser os sintomas mais comuns nesses pacientes. O objetivo deste estudo foi examinar 
a prevalência de sintomas em pacientes com câncer de pulmão a fim de identificar subgrupos (clusters) de 
pacientes, agrupados de acordo com a magnitude dos sintomas, bem como comparar os subgrupos quanto 
à qualidade de vida. Métodos: Estudo transversal utilizando agrupamento hierárquico aglomerativo. Foram 
avaliadas as características demográficas de 50 pacientes com câncer de pulmão, bem como sua pontuação 
em três questionários de qualidade de vida: o 30-item European Organization for Research and Treatment of 
Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30), o Functional Assessment of Cancer Therapy-Lung 
e o Medical Outcomes Study 36-item Short-form Survey. A análise de agrupamentos (clusters) levou em conta 
a magnitude dos sintomas de maior prevalência de acordo com as escalas de sintomas do EORTC QLQC-30; 
esses sintomas foram fadiga, dor, dispneia e insônia. Resultados: Foram identificados três agrupamentos 
(subgrupos) de pacientes, baseados na magnitude dos quatro sintomas mais prevalentes. Os três subgrupos de 
pacientes foram os seguintes: pacientes com sintomas leves (n = 30; 60%); pacientes com sintomas moderados 
(n = 14; 28%) e pacientes com sintomas graves (n = 6; 12%). O subgrupo de pacientes com sintomas graves 
apresentou a pior qualidade de vida, conforme mensurada pelos escores totais e pelas dimensões integradas dos 
três instrumentos. Conclusões: Este estudo destaca a importância da avaliação de agrupamentos de sintomas 
como uma ferramenta relevante para medir a qualidade de vida de pacientes com doenças crônicas, como o 
câncer de pulmão.
Descritores: Sinais e sintomas; Análise por conglomerados; Neoplasias pulmonares; Qualidade de vida; 
Questionários; Assistência Paliativa.
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to compare quality of life among subgroups of 
patients with symptoms of different magnitude.
Methods
We conducted a cross-sectional study involving 
a convenience sample of 50 consecutive patients 
who were clinically stable after having received 
lung cancer treatment. The patients were selected 
from among those treated at the Federal University 
of São Paulo Hospital São Paulo Lung Cancer 
Outpatient Clinic, located in the city of São Paulo, 
Brazil. The study was approved by the Research 
Ethics Committee of the Federal University of São 
Paulo, and all of the participants gave written 
informed consent.
The inclusion criteria were as follows: being 
18 years of age or older; having histologically 
proven lung cancer; having a Mini-Mental State 
Examination score of at least 21(11); and having 
been clinically stable for at least 10 days before 
the beginning of the evaluation. Clinical stability 
was defined as no changes in cough, sputum, 
or dyspnea (as assessed by a structured form 
filled out during outpatient follow-up), as well 
as being defined as no hospitalizations and no 
modifications in the therapeutic regimen. The 
exclusion criterion was having declined to answer 
any of the questions.
Clinical evaluations and physical examinations 
were performed by the team of attending physicians 
and were based on a structured form. All patients 
met the stability criteria.
In the first visit (at enrollment in the study), we 
collected data regarding the following independent 
variables: gender; age; smoking status; smoking 
history; histological subtype (non-small cell lung 
cancer or small cell lung cancer); staging, in 
accordance with the 1997 tumor-node-metastasis 
classification(12); Karnofsky performance status(13); 
Mini-Mental State Examination score(14); and the 
scores on the Brazilian Portuguese-language 
versions of three quality of life questionnaires, 
namely the 30-item European Organization for 
Research and Treatment of Cancer Core Quality 
of Life Questionnaire (EORTC QLQ-C30),(15) the 
Functional Assessment of Cancer Therapy-Lung 
(FACT-L),(16) and the Medical Outcomes Study 
36-item Short-form Survey (SF-36).(17)
In order to determine the prevalence and 
magnitude of symptoms, a domain known as 
“symptom experience”,(6,18) we used the EORTC 
QLQ-C30, which assesses 8 cancer-related 
Introduction
Lung cancer continues to be the leading cause 
of cancer death. Given that smoking and air 
pollution cannot be controlled in the short term, 
it is likely that the incidence of lung cancer will 
continue to increase.(1) In addition, the prognosis 
for lung cancer patients (especially those with 
advanced disease) is not favorable, despite advances 
in medicine, biology, and technology.(2)
Patients with lung cancer often experience 
profound physical and psychosocial changes as 
a result of disease progression or treatment side 
effects.(3-5) It has been suggested that patients 
with lung cancer experience greater symptom-
related distress than do patients with other types 
of cancer, especially near the end of life.(3) Fatigue, 
pain, dyspnea, depression, and sleep disturbances 
appear to be the most common symptoms in 
lung cancer patients.(4)
The occurrence of multiple symptoms predicts 
changes in patient function, treatment failure, 
and post-treatment outcomes.(4) A symptom 
cluster is defined as a stable group of two or 
more concurrent symptoms that are related to 
one another and independent of other symptom 
clusters.(6) Oncology studies have shown that 
combinations or clusters of symptoms are of 
greater importance than are individual symptoms. 
Such concurrent symptoms likely have a 
multiplicative nature, a catalytic effect on one 
another,(7) according to the theory of unpleasant 
symptoms, as well as having a synergistic influence 
on behavioral, functional, and quality of life 
outcomes.(8,9)
It is noteworthy that quality of life has become 
a significant topic in lung cancer research and 
practice. Quality of life assessment can help health 
care providers to identify subgroups of lung cancer 
patients and make specific interventions in each 
subgroup of patients. In addition, quality of life 
can be a predictor of lung cancer morbidity and 
mortality.(2,10)
Although many studies have described 
symptoms as being a major aspect of morbidity 
in cancer patients, only a few studies have 
examined the relationship between symptoms 
and quality of life in patients with lung cancer. 
Therefore, the objectives of the present study 
are as follows: to examine the prevalence of 
symptoms in patients with lung cancer; to identify 
subgroups (clusters) of lung cancer patients on 
the basis of the magnitude of the symptoms; and 
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general health, vitality, social functioning, role-
emotional, and mental health; the scores for each 
domain can range from 0 (severe debilitation) 
to 100 (asymptomatic).(17,22,23)
Patients completed the questionnaire by 
answering each question after it was read to 
them by an interviewer, all interviews having been 
performed by the same interviewer. This approach 
was chosen on the basis of our previous experience 
working with a population in which the proportion 
of individuals showing functional illiteracy was 
high. The interviews were performed in a quiet 
environment, no interruptions being allowed. The 
interviewer reviewed each questionnaire after the 
end of the interview in order to confirm that all 
of the questions had been answered.
Cluster analysis is a descriptive technique 
that is used in order to identify subgroups of 
patients who are similar to one another.(7,18) 
Our cluster analysis took into account a set of 
symptom magnitude measurements obtained 
by the EORTC QLQ-C30 symptom scales, the 
symptoms including fatigue, pain, dyspnea, and 
insomnia (i.e., the most prevalent symptoms). 
Evaluation of these symptoms does not constitute 
a standardized method for evaluating functional 
capacity and global quality of life. We adopted 
a hierarchical approach because we had no way 
of knowing how many clusters we would find.(24) 
By means of hierarchical clustering, patients 
who have similar patterns across symptoms can 
be grouped into clusters and subgroups can be 
formed on the basis of symptom experience. The 
agglomerative schedule, the farthest neighbor 
method, and the squared Euclidean distance 
were used as dissimilarity measures. Because 
cluster analysis has no likelihood-based goodness-
of-fit indices, the appropriate number of cluster 
solutions was determined by dendrograms and the 
expert judgment of the researchers, the number 
of individuals in each group being limited to 
no more than 10% of the sample.(25) The cluster 
solution used in the present study was verified 
with clinical assessments regarding the profile 
of symptom means for each group, to be sure 
that the groups differed in evaluation across 
the set of symptoms.(26)
One-way ANOVA (corrected by the Bonferroni 
test) was used in order to compare the 
characteristics of the patients who were grouped 
by the best cluster solution. The following variables 
were included: age; Karnofsky performance 
symptoms and the side effects of the primary 
treatment. This instrument consists of a 4-point 
scale, with answers whose scores can range from 
1 (not at all) to 4 (very much).(19) Symptoms of 
higher prevalence (over 50%) were considered 
for inclusion in the cluster analysis.
The EORTC QLQ-C30 consists of 30 items 
that cover health issues that are relevant to a 
wide range of cancer patients. Of those 30 items, 
13 are grouped into scales measuring cancer-
related symptoms (fatigue, pain, nausea/vomiting, 
dyspnea, insomnia, appetite loss, constipation, and 
diarrhea, all of which are used in order to assess 
the prevalence and magnitude of lung cancer 
symptoms) and the perceived economic impact of 
the disease and treatment. The remaining 17 items 
(which are used in order to assess quality of life) 
are grouped into 5 functional scales (physical, role, 
emotional, cognitive, and social functioning) and 
one global health status/quality of life scale.(19,20) 
The functional and global health status scale 
scores can range from 0 (severe debilitation) 
to 100 (asymptomatic), and the symptom scale 
scores can range from 0 (asymptomatic) to 100 
(severe debilitation). The Brazilian Portuguese-
language version of the EORTC QLQ-C30 has 
been validated for use in Brazil.(15)
In order to assess the quality of life, we 
administered the EORTC QLQ-C30, the FACT-L, 
and the SF-36. We chose to use two specific 
questionnaires and one generic questionnaire 
in order to increase the discriminative power of 
the data for cluster analysis.
The FACT-L (version 4) is a 36-item compilation 
of disease-specific, domain-additional concerns 
for lung cancer patients, subdivided into four 
primary quality of life domains of the Functional 
Assessment of Cancer Therapy-General (physical, 
social/family, emotional, and functional domains) 
plus an additional 9 items specific for lung 
cancer. The total FACT-L score can range from 
0 (asymptomatic) to 108 (severe debilitation). 
The FACT-L generates an index known as the 
FACT-L Trial Outcome Index (FACT-L TOI). 
The FACT-L TOI is derived from the sum of the 
scores obtained on some of the subscales that 
constitute the FACT-L, being primarily used for 
functional capacity evaluation and ranging from 
0 (asymptomatic) to 84 (severe debilitation).(20,21)
The SF-36 is a generic quality of life 
questionnaire that consists of 8 domains, namely 
physical functioning, role-physical, bodily pain, 
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clusters appeared to be distinct from one another 
on visual inspection of the dendrogram (Figure 1). 
The three subgroups of patients were as follows: 
patients with mild symptoms (n = 30; 60%); 
patients with moderate symptoms (n = 14; 28%); 
and patients with severe symptoms (n = 6; 12%).
The characteristics of the patients and 
the description of the clusters are shown in 
Table 2. Most of the study participants were 
male (68%), were in the 27-81 year age bracket, 
were former smokers (84%), and had a low level 
of education (64%). In addition, most (90%) of 
status; smoking history (in pack-years); SF-36 
score; EORTC QLQ-C30 score; and FACT-L score. 
Pearson’s chi-square test was used in order to 
compare the clusters in terms of gender, histological 
subtype, staging, smoking history, and level of 
education.
The data were analyzed with the IBM SPSS 
Statistics software package, version 19.0 for 
Windows (IBM Corporation, Armonk, NY, USA). 
The type I error for all tests was set at 0.05.
Results
Fifty patients with lung cancer were evaluated 
in terms of the prevalence and magnitude of 
their symptoms, as assessed by their EORTC 
QLQ-C30 symptom scale scores. As can be seen 
in Table 1, the most prevalent symptoms and 
their magnitude scores were as follows: fatigue 
(26.9); pain (31.4); dyspnea (35.0); and insomnia 
(39.2). Of the 50 lung cancer patients studied, 
24% reported experiencing all four symptoms, 
28% reported experiencing three of the four 
symptoms, 22% reported experiencing two of 
the four symptoms, 10% reported experiencing 
one of the four symptoms, and 16% reported 
experiencing none of those symptoms.
A distinct and interpretable three-cluster 
solution was identified on the basis of the 
magnitude of the four most prevalent symptoms 
(fatigue, dyspnea, insomnia, and pain). Three 
Figure 1 - Dendrogram obtained by using the farthest neighbor method. Clusters were formed on the basis 
of the distances between individual magnitudes of symptoms.
Table 1 - Prevalence of symptoms and mean 30-item 
European Organization for Research and Treatment of 
Cancer Core Quality of Life Questionnaire symptom 
scores in the 50 lung cancer patients studied.
Symptom Prevalence (%) Mean Score (SD)
EORTC QLQ-C30
Fatigue 66 26.9 (30.1)
Nausea and vomiting 26 12.7 (25.1)
Pain 58 26.0 (31.4)
Dyspnea 56 32.0 (35.0)
Insomnia 54 36.0 (39.2)
Appetite loss 42 22.7 (31.9)
Constipation 24 14.0 (28.6)
Diarrhea 4 4.0 (19.8)
EORTC QLQ-C30: 30-item European Organization for 
Research and Treatment of Cancer Core Quality of Life 
Questionnaire.
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hoc Bonferroni correction showed significant 
associations between questionnaire domains 
and symptom severity as defined by hierarchical 
clustering.
The patients with severe symptoms were found 
to have the worst quality of life, as assessed by 
total scores and integrated domains of all three 
instruments (Figure 2). The difference among the 
three subgroups in terms of the quality of life 
scores reached the minimal clinically important 
difference established for each questionnaire.(19-22).
Discussion
Our cluster analysis was based on the 
magnitude of fatigue, pain, dyspnea, and insomnia, 
having identified three clusters (subgroups) of 
patients, namely those with mild symptoms, those 
with moderate symptoms, and those with severe 
symptoms. Cluster analysis is recognized as an 
important method that can assist in understanding 
the relationship between multiple concurrent 
cancer symptoms and patient quality of life.(27,28) 
In the present study, agglomerative hierarchical 
the participants were diagnosed with non-small 
cell lung cancer, and most (78%) were diagnosed 
with stage I-III non-small cell lung cancer. In 
comparison with the subgroups of patients with 
mild and moderate symptoms, the subgroup 
of patients with severe symptoms comprised a 
larger number of patients in advanced stages 
(p = 0.007), showing a significant decrease in 
the Karnofsky performance status (p = 0.001). 
There were no significant differences among 
the three subgroups of patients in terms of the 
proportion of males, smoking status, histological 
subtypes, or level of education. The symptom 
scores increased across the cluster severity strata.
For the evaluation of quality of life, the 
mean scores for each of the scales of the 
EORTC QLQ-C30, the FACT-L, and the SF-36 
were stratified by the cluster solution. Physical 
and functional aspects were the aspects that 
were most affected by the magnitude of the 
symptoms, regardless of the instrument used 
for measuring quality of life (Table 3). As can 
be seen in Table 3, one-way ANOVA with post 
Table 2 - Demographic characteristics of the 50 lung cancer patients studied.
Variable Total
Subgroup
Mild 
symptoms
Moderate 
symptoms
Severe 
symptoms
n (%) 50 (100) 30 (60) 14 (28) 6 (12)
Age (years) mean (SD) 61.3 (10.1) 60.5 (11.7) 63.4 (10.7) 61.9 (10.9)
Male gender, n (%) 34 (68) 22 (73.3) 9 (64.3) 3 (50)
Smoking history
Former smoker, n (%) 42 (84) 25 (83.3) 11 (78.6) 6 (100)
Never smoker, n (%) 8 (16) 5 (16.7) 3 (21.4) 0 (0)
Pack-years, mean (SD) 44.2 (31.2) 43.0 (29.9) 42.4 (39.0) 54.7 (15.1)
Histological subtypes, n (%)
SCLC 5 (10.0) 3 (10.0) 1 (7.1) 1 (16.7)
NSCLC 45 (90.0) 27 (90.0) 13 (92.9) 5 (83.3)
Karnofsky performance status, mean (SD) # 91.4 (11.8) 95 (9.4) 90 (10.4) 76.7 (15.1)
Staging, n (%) §
I-III 39 (78.0) 27 (90.0) 10 (71.4) 2 (33.3)
IV 11 (22.0) 3 (10.0) 4 (28.6) 4 (66.7)
MMSE score, mean (SD) 27.4 (2.3) 27.7 (2.2) 27.6 (2.2) 25.8 (2.3)
Level of education, n (%)
Illiterate 1 (2) 0 (0) 0 (0) 1 (16.7)
9 years of schooling 32 (64) 17 (56.7) 10 (71.4) 5 (83.3)
High school 13 (26) 11 (36.7) 2 (14.3) 0 (0)
College 4 (8) 2 (6.7) 2 (14.3) 0 (0)
NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; and MMSE: Mini-Mental State Examination. # ANOVA 
(with post hoc Bonferroni correction) revealed significant differences between the patients with severe symptoms and 
those with mild or moderate symptoms. § Pearson’s chi-square test; p < 0.05.
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Table 3 - Mean scores (and standard deviations) on the 30-item European Organization for Research and 
Treatment of Cancer Core Quality of Life Questionnaire, the Functional Assessment of Cancer Therapy-Lung, 
and the Medical Outcomes Study 36-item Short-form Health Survey for the 50 lung cancer patients studied. 
Questionnaire Total
Subgroup
pSymptom severity
Mild Moderate Severe 
EORTC QLQ-C30
Global health status 70.83 (25.6) 75.8 (26.3) 65.5 (19.2) 58.3 (32.5) NS
Physical functioning 70.13 (27.7) 77.3 (22.5) 72.8 (17.4) 27.8 (35.9) < 0.001
Role functioning 70.33 (32.3) 78.9 (30.3) 70.2 (18.7) 27.8 (37.5) 0.001
Emotional functioning 69.67 (23.7) 77.2 (21.4) 61.9 (16.6) 50.0 (33.7) 0.010
Cognitive functioning 79.00 (23.7) 83.3 (23.6) 76.2 (20.4) 63.9 (28.7) NS
Social functioning 82.33 (31.1) 85.6 (27.6) 89.3 (24.9) 50.0 (44.7) 0.020
FACT-L
Physical well-being 21.66 (6.1) 22.8 (5.9) 22.3 (4.2) 14.7 (6.7) 0.009
Social/family well-being 19.78 (5.7) 20.7 (5.4) 18.4 (6.5) 18.5 (4.7) NS
Emotional well-being 18.44 (4.6) 18.5 (5.4) 18.1 (3.3) 18.8 (3.3) NS
Functional well-being 16.64 (7.2) 18.9 (7.6) 14.4 (4.6) 10.5 (5.9) 0.010
FACT-G 76.52 (18.0) 80.9 (19.6) 73.1 (12.6) 62.5 (12.9) 0.049
FACT-L 95.80 (21.7) 101.6 (22.7) 92.7 (14.9) 74.0 (15.9) 0.010
FACT-L TOI 57.58 (16.3) 62.4 (15.9) 56.2 (9.5) 36.7 (5.9) 0.001
SF-36
Physical functioning 61.7 (30.4) 68.5 (28.6) 62.9 (23.2) 25.0 (31.9) 0.004
Role-physical 40.5 (42.5) 51.7 (44.5) 28.6 (37.6) 12.5 (20.9) NS
General health 64.7 (23.1) 67.7 (24.8) 61.6 (16.2) 56.8 (28.9) NS
Vitality 60.0 (29.1) 68.7 (26.7) 54.3 (22.9) 30.0 (29.1) 0.006
Social functioning 67.8 (31.9) 78.3 (27.1) 58.1 (30.1) 37.5 (37.1) 0.005
Role-emotional 49.3 (45.3) 63.3 (44.9) 28.6 (38.9) 27.8 (38.9) 0.024
Mental health 66.6 (21.4) 71.9 (21.3) 62.3 (15.5) 50.0 (26.1) 0.047
Total 59.7 (24.5) 68.1 (24.5) 52.1 (17.1) 35.1 (17.7) 0.003
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; 
FACT-L: Functional Assessment of Cancer Therapy-Lung; FACT-G: Functional Assessment of Cancer Therapy-General; 
TOI: Trial Outcome Index; SF-36: Medical Outcomes Study 36-item Short-Form Health Survey; and NS: not significant. 
ANOVA (with post hoc Bonferroni correction) revealed significant differences between the patients with severe symptoms 
and those with mild or moderate symptoms.
clustering allowed the identification of subgroups 
of patients grouped by symptom experience, 
demonstrating the association between symptom 
clusters and quality of life. Therefore, we assessed 
not only the prevalence of symptoms but also the 
severity of the symptoms within the cluster.(28)
Increases in the magnitude of symptoms were 
found to have a negative association with the 
quality of life of the lung cancer patients in 
the present study. Our data analysis showed 
significant differences among the subgroups 
of patients in terms of the scores obtained on 
several of the domains of the quality of life 
questionnaires used in the present study. In 
general, the subgroup of patients with higher 
scores for all four symptoms (i.e., the subgroup 
of patients with severe symptoms) showed a 
strong trend toward worse quality of life, whereas 
the subgroups of patients with lower symptom 
scores were found to have better quality of life 
(as assessed by all three questionnaires used in 
the present study).
The patients with severe symptoms had 
significantly lower scores on physical and functional 
domains of the EORTC QLQ-C30, the FACT-L, 
and the SF-36. This finding is consistent with 
those of previous studies involving patients with 
lung cancer(8,29) and corroborates the importance 
of the presence and magnitude of symptoms as 
a correlate of impaired quality of life in lung 
cancer patients.
In the present study, the patients with severe 
symptoms had the lowest total FACT-L scores 
(i.e., the lowest Functional Assessment of Cancer 
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which significantly interfere with the functional 
capacity of patients.(30)
The present study has some limitations. The 
study focused on four symptoms (fatigue, pain, 
dyspnea, and insomnia). These symptoms were 
chosen on the basis of a previous analysis of 
the collected data. Future studies evaluating 
lung cancer patients can include additional 
symptoms. Because our study sample consisted 
mostly of elderly patients, our findings should 
not be generalized to individuals of other ages, 
especially younger patients. Finally, the present 
study used a cross-sectional design, which means 
that changes in symptom clusters over time were 
not investigated.(28) Therefore, the study design 
does not allow us to interpret the symptom cluster 
as a causal predictor of reduced quality of life in 
lung cancer patients, longitudinal studies being 
therefore required.
In conclusion, the present study provides 
an experimental basis for focusing on cluster 
analyses of symptoms and the associated quality 
of life outcomes in patients with lung cancer. The 
present study demonstrates that symptom cluster 
assessment is an important tool to minimize the 
inaccuracies introduced by unstructured symptom 
assessment. Ultimately, the recognition of the 
importance of symptom clusters can change 
Therapy-General and FACT-L scores, as well as 
the lowest FACT-L TOI). These symptoms can also 
cause anxiety, which interferes with the emotional 
well-being of patients. Although the patients with 
severe symptoms had the lowest scores on the 
EORTC QLQ-C30 and SF-36 emotional and social 
domains, there were no significant differences 
among the three subgroups of patients in terms 
of their scores on the FACT-L emotional and 
social domains. This shows that, despite having 
similarly named domains, the three quality of 
life questionnaires used in the present study 
differ in terms of the contents that they assess.
The total SF-36 scores and the SF-36 vitality 
domain scores were significantly lower in the 
patients with severe symptoms than in those 
with mild or moderate symptoms. These factors 
are directly influenced by the symptom itself, 
especially fatigue.
We found no differences among the three 
subgroups of patients in terms of demographic 
factors, the exception being staging; the prevalence 
of advanced-stage disease was higher in the 
patients with severe symptoms than in those 
with mild or moderate symptoms. It is known 
that patients with progressive disease have a 
higher prevalence of uncontrolled symptoms 
(especially fatigue, pain, dyspnea, and anorexia), 
Figure 2 - In A, mean 30-item European Organization for Research and Treatment of Cancer Core Quality 
of Life Questionnaire (EORTC QLQ-C30) domain scores for the subgroups of patients with mild, moderate, 
and severe symptoms (as identified by cluster analysis). In B, mean Functional Assessment of Cancer Therapy-
Lung (FACT-L) scores, mean Functional Assessment of Cancer Therapy-General (FACT-G) scores, and mean 
Functional Assessment of Cancer Therapy-Lung Trial Outcome Index (FACT-L TOI) for the subgroups of 
patients with mild, moderate, and severe symptoms (as identified by cluster analysis).
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